Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0519-0130 dose-finding study in chronic kidney disease with overweight or obesity
jRCT2031240497Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2024
- Modality
- Recombinant Proteins and Enzymes, Peptides, Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of NNC0519-0130 and semaglutide in chronic kidney disease (CKD), obesity, Overweight and 1 more (9 arms), sponsored by Novo Nordisk. Primary endpoint: Dose-response relationship for relative reduction in UACR. Started Dec 2024; status: completed.
02
Drugs
NNC0519-0130semaglutide
03
Conditions
chronic kidney disease (CKD)obesityOverweighttype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCT2031240497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240497.